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The present study describes the development and subsequent validation of simple and accurate stability 
indicating RP-HPLC method for the determination of sparfloxacin and dexamethasone in pharmaceutical 
formulations in the presence of their stress-induced degradation products. Both the drugs and their 
stress-induced degradation products were separated within 10 minutes using C8 column and mixture of 
methanol and 0.02 M phosphate buffer pH 3.0 (60:40 v/v, respectively) as mobile phase at 270 nm using 
diode array detector. Regression analysis showed linearity in the range of 15-105 µg/mL for sparfloxacin 
and 5-35 µg/mL for dexamethasone. All the analytes were adequately resolved with acceptable tailing. 
Peak purity of the two drugs was also greater than 0.9999, showing no co-elution peaks. The developed 
method was applied for simultaneous determination of sparfloxacin and dexamethasone in pharmaceutical 
formulations for stability studies.
Uniterms: RP-HPLC. Sparfloxacin. Dexamethasone. Degradation products. Stability studies.
O presente estudo descreve o desenvolvimento e a subsequente validação de indicador de estabilidade 
simples e acurada por RP-HPLC para a determinação de esparfloxacino e dexametasona em formulações 
farmacêuticas na presença de produtos de degradação induzidos por estresse. Tanto os fármacos quanto 
os produtos de degradação induzidos pelo estresse foram separados em 10 minutos, utilizando coluna 
C8 e mistura de methanol e tampão fosfato 0,02 M, pH 3,0 (60:40 v/v, respectivamente) como fase 
móvel e detector de arranjo de diodo a 270 nm, A análise de regressão mostrou linearidade na faixa de 
15-105 µg/mL para esparfloxacino e 5-35 µg/mL para a dexametsona. Todos os analitos foram resolvidos 
adequadamente com tailing aceitável. O pico de pureza dos dois foi maior que 0.9999, não mostrando 
picos de co-eluição. O método desenvolvido foi aplicado para a determinação simultânea de esparfloxacino 
e dexametasona em formulações farmacêuticas e para estudos de estabilidade. 
Unitermos: RP-HPLC. Esparfloxacino. Dexametasona. Produtos de degradação. Estudos de estabilidade.
INTRODUCTION
ICH and WHO recommended that analysis of 
pharmaceutical finished products during stability 
testing should be conducted by use of a validated 
stability-indicating method. In this study ICH and 
WHO recommendations were therefore kept in mind 
for the simultaneous determination of sparfloxacin and 
dexamethasone.
Sparfloxacin is chemically designated as 5-amino-
1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-
difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic 
acid (Figure 1). It is a broad spectrum antibiotic 
and is used for the treatment of bacterial corneal 
infections, bacterial conjunctivitis and corneal ulcer 
to control the infections of the eye (Reynolds, 2009). 
Dexamethasone (Figure 1) chemically designated as 
(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-
dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H- 
cyclopenta[a]phenanthren-3-one is a corticosteroid, used 
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primarily for inflammatory ocular conditions (Reynolds, 
2009). Individually sparfloxacin and dexamethasone have 
been analysed by various techniques. The techniques used 
for sparfloxacin include HPLC (Marona, Schapoval, 1999, 
2001; Marona, Zuanazzi, Schapoval, 1999; Salgado et 
al., 2005; Al-Sayed, 1995), HPTLC (Mody et al., 1998), 
UV/VIS (Marona, Schapoval, 1999, 2001) and LC-MS 
(Noh et al., 2010). The analytical methods existed for 
dexamethasone include determination by HPLC (Iqbal et 
al., 2006; Huetos et al., 1999; Mallinson et al., 1995; Chen 
et al., 2008; Gallegos, Arroyo, 2002; Urban, Mainardes, 
Gremiao, 2009; Kwak, D’Amico, 1995), GC-MS 
(Mallinson et al., 1995) and thin layer chromatography 
(Huetos et al., 1999). 
 
The combination of sparfloxacin and dexamethasone 
has not been adopted by any official pharmacopoeia. 
An extensive review of the literature did not reveal 
any stability indicating HPLC method (with forced 
degradation studies) for simultaneous determination of 
both drugs. Therefore attempts were made to develop 
and validate simple and precise stability indicating RP-
HPLC method for simultaneous determination of both 
drugs and their stress induced degradation products in 
pharmaceutical formulations. We are currently engaged 
in developing new HPLC methods for different classes 
of drugs in binary combination either in pharmaceutical 
formulations or in human plasma (Qutab et al., 2007a,b, 
2009; Ashfaq et al., 2007; Ashfaq, Khan, Asghar, 2008; 
Khan et al., 2008, 2010, 2012; Khan, Jilani, Ashfaq, 
2010; Sharif et al., 2010.; Razzaq et al., 2012a,b,c,d). The 
present research work is a continuation of the work we 
have already reported.
MATERIAL AND METHODS
Chemicals and Reagents 
Pure Reference standards (secondary standards) of 
sparfloxacin and dexamethasone with declared purity of 
99.50 and 99.96% respectively were obtained from Schazoo 
Zaka Laboratories (Lahore, Pakistan). Spar-D eye drops 
(Biomedica International) claimed to contain 3 µg/mL 
of sparfloxacin and 1 µg/mL of dexamethasone (base) 
were used in this study. Methanol was of HPLC grade, 
whereas all other chemicals and reagents used in this 
study were of analytical reagent grade and were procured 
from M.S Traders Lahore, Pakistan (Fluka origin). Double 
distilled water was used for all the experiments. Filtration 
of the mobile phase was done using 0.45 mm nylon filters 
(Millipore, USA).
Equipment and chromatographic conditions
The HPLC system consisted of Shimadzu LC-20A 
system (Kyoto, Japan) equipped with model LC-20AT 
pump, SPD-M20A Diode array detector (set at 270 nm), 
and DGU-20A5 online degasser, and a Rheodyne injection 
valve with a 20 µL loop. Peak areas were integrated 
using a Shimadzu LC solution (version 1.227) software 
program. Experimental conditions were optimized on 
a Hypersil C 8 column (250 X 4.6 mm, 5 µm) at room 
temperature. Mobile phase was prepared by mixing 0.02 M 
phosphate buffer and methanol in ratio of 40:60 v/v, 
respectively. Phosphate buffer was prepared by dissolving 
2.72 g of potassium dihydrogen phosphate in 1000 mL 
of water. Its pH was adjusted to 3.0 with phosphoric 
acid after the addition of 1 mL of triethylamine. Mobile 
phase was flowed at 1.5 mL/min and all chromatographic 
experiments were performed at room temperature 
(25 oC ± 2 oC).
Preparation of standard solution
Standard stock solution of the two drugs was 
prepared by accurately weighing 37.5 mg sparfloxacin 
and 12.5 mg dexamethasone and then dissolved in few 
mL of methanol. The volume of this solution was then 
marked to 25 mL with 0.1 M sodium hydroxide and 
sonicated for 10 minutes. To prepare working standard 
solution, 1 mL of the above solution was diluted to 
25 mL with mobile phase. The solution so obtained 
has concentration equal to 60 µg/mL sparfloxacin and 
20 µg/mL dexamethasone. The solution was filtered 
using nylon filter before analysis.
Preparation of sample solution 
1 mL commercial eye drop was diluted to 50 mL 
with mobile phase to obtain concentration equal to 
60 µg/mL sparfloxacin and 20 µg/mL dexamethasone. The 
solution was filtered using nylon filter before analysis.
FIGURE 1 - Chemical structures of sparfloxacin (A) and 
dexamethasone (B).
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Linearity
Linear calibration plots of the proposed method were 
obtained over concentration ranges of 15-105 µg/mL (15, 
30, 45, 60, 75, 90 and 105 µg/mL) for sparfloxacin and 
5-35 µg/mL dexamethasone (5, 10, 15, 20, 25, 30 and 35 
µg/mL). Triplicate analysis of each solution was carried 
out.
Accuracy
To demonstrate the accuracy of the proposed method, 
standard addition method was used. For this purpose, 
known quantities of sparfloxacin and dexamethasone 
were supplemented to the sample solution previously 
analysed. The results of this solution were compared with 
the true results. Three levels of solutions in the range of 
50-150% of nominal analytical concentration (60 µg/mL 
sparfloxacin and 20 µg/mL dexamethasone) were prepared 
and analyzed.
Precision
Intra-day and inter-day precision was calculated to 
perform precision. Intra-day precision was measured by 
analyzing three different concentrations five times within 
the same day and inter-day precision were determined by 
evaluating the response of same solutions for three days. 
RSD of the peak area was then calculated.
Specificity (Stress Testing)
For specificity demonstration, acidic, basic, 
oxidative, thermal and photolytic stresses were applied as 
described by ICH in its guidelines. All stress studies were 
performed in 25 mL volumetric flask.
Acid Degradation Studies
Acid degradation study was performed in versatile 
environmental test chamber (Sanyo, Japan) at 40 oC/75% 
RH using 5 M HCl. For this purpose, 1 mL of the standard 
stock solution and 1 mL of 5 M HCl were taken in 25 mL 
volumetric flask and then kept in versatile environmental 
test chamber at 40 oC/75% RH. After 22 hours, those 
solutions were neutralized using 5 M sodium hydroxide 
and finally completed till the mark with mobile phase.
Base Degradation Studies 
Base degradation study was performed in versatile 
environmental test chamber (Sanyo, Japan) at 40 oC/75% 
RH and at 22 oC/49% RH using 5 M NaOH. For this 
purpose, 1 mL of the standard stock solution and 1 mL 
of 5 M NaOH were taken in 25 mL volumetric flask and 
then kept in versatile environmental test chamber at 
40 oC/75% RH for 16 h and at 22 oC/49% RH for forty 
five minutes. After the stated times, the solutions were 
neutralized using 5 M HCl and completed till the mark 
with mobile phase.
Oxidative Degradation Studies
Oxidative degradation study was performed in 
versatile environmental test chamber (Sanyo, Japan) at 
40 oC/75% RH using 6% H2O2. For this purpose, 1 mL 
of the standard stock solution and 1 mL of 6% H2O2 were 
taken in 25 mL volumetric flasks and then kept in versatile 
environmental test chamber at 40 oC/75% RH for 22 h. 
After completion of the stress, the flask was completed 
till the mark with mobile phase.
Thermal Degradation Studies
Thermal degradation study was performed in 
versatile environmental test chamber (Sanyo, Japan) at 
40 oC/75% RH. For this purpose, 1 mL of the standard 
stock solution in 25 mL volumetric flask was kept in 
versatile environmental test chamber at 40 oC/75% RH for 
22 h. After completion of the stress, the 25 mL flask was 
completed till the mark with mobile phase.
Photolytic Degradation Studies
For photolytic degradation study, 1 mL of the 
standard stock solution in 25 mL volumetric flask was 
placed in the direct sunlight. After 1.25 h, the flask was 
completed with mobile phase till the mark.
Robustness
Premeditate variations were performed in the 
experimental conditions of the proposed method to assess 
the method robustness. For this, faint modifications 
were made in the operating conditions like mobile phase 
composition, flow rate and pH of buffer solution. The 
effect of these changes on chromatographic results was 
then measured.
RESULTS AND DISCUSSION
In this study, we developed a simple, sensitive 
and accurate RP-HPLC method for the separation 
of sparfloxacin and dexamethasone and their stress 
induced degradation products using C8 column. In order 
to obtain symmetrical peaks with better resolution, 
the chromatographic conditions i.e. pH of the buffer, 
concentration of organic modifier and flow rate of the 
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mobile phase were optimized. During first phase of this 
method development both methanol and acetonitrile were 
tried as organic content of the mobile phase along with 
phosphate buffer (pH 3.0; 20 mM) in order to get the 
peaks with better selectivity and good resolution. Use of 
acetonitrile resulted in broader peaks, whereas better peaks 
were obtained using methanol. Increase in temperature 
of the column oven from 30 to 50 oC did not improve the 
peak shapes of the analytes during acetonitrile use. So 
finally methanol was selected as organic portion of the 
mobile phase.
For selection of the buffer, phosphate buffer (pH 
3.0; 0.02M) was taken because some researchers have 
used acid medium for the separation of corticosteroids 
and quinolones (Schil, Charles, 1994).
Hydrogen ion concentration has a definite control on 
the retention properties of substances so its influence on the 
separation efficiency of sparfloxacin and dexamethasone 
was studied. Different phosphate buffer solutions of the 
same strength but different pH (3, 4, 5, 6 and 7) were 
prepared to check the separation efficiency under different 
acidic conditions. The use of buffers of different pH did 
not result in change in retention times of the analytes but 
results in peaks with variable asymmetry. In all those 
conditions except at pH 3, there was considerable peak 
tailing for sparfloxacin, so pH 3 was finally selected for 
further studies.
The percentage of methanol in the mobile phase 
was varied from 40 to 80% in order to check the effect of 
organic modifier on the separation efficiency of the two 
analytes. Obviously, in RP-chromatography decreasing 
the polarity of the mobile phase results in faster elution 
so increasing concentration of methanol decreased the 
retention time of the analytes. Peaks with maximum 
selectivity and with all the chromatographic parameters 
within acceptable range were observed when using 60% 
methanol and 40% buffer within eight minutes as can be 
seen in Figure 2.
ICH guidelines were kept in practice for validation of 
the method (ICH,1996). Validation parameters performed 
include linearity, accuracy, precision, robustness, 
specificity, detection limit and quantitation limit.
Linear calibration plots for the proposed method 
were obtained in concentration ranges of 15-105 µg/mL 
(15, 30, 45, 60, 75, 90 and 105 µg/mL) for sparfloxacin 
and 5-35 µg/mL dexamethasone (5, 10, 15, 20, 25, 30 and 
35 µg/mL). The linear regression equation for sparfloxacin 
was found to be Y= 51523 X + 7651 with correlation 
coefficient equal to 0.999 whereas for dexamethasone, 
it was Y= 81718 X + 2313 with correlation coefficient 
equal to 0.999.
The detection limit (DL) and quantitation limit 
(QL) were determined by making different solution with 
decreasing concentrations. DL was found to be 0.45 µg/mL 
and 0.15 µg/mL for sparfloxacin and dexamethasone, 
respectively (S/N ratio 3:1). QL was found to be 1.36 µg/mL 
and 0.45 µg/mL for sparfloxacin and dexamethasone, 
respectively (S/N ratio 10:1).
Accuracy of the method was performed by the 
standard addition technique. Three levels of solutions (50, 
FIGURE 2 - Chromatogram of sparfloxacin (tR = 3.415) and dexamethasone (tR = 7.792) in pharmaceutical formulations. 
Chromatographic conditions: mobile phase methanol: 0.02 M phosphate buffer (60:40, v/v), pH 3.0, Column BDS Hypersil C8 
(250 X 4.6, 5µm), flow rate 1.5 mL min-1, injection volume 20 µL, wavelength 270 nm. Concentration: 60 µg/mL sparfloxacin 
and 20 µg/mL dexamethasone.
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TABLE I - Accuracy of the Proposed HPLC Method
Drugs
Spiked 
concentration*
(µg/mL) 
Measured 
concentration*
 (µg/mL) ± SD; 
RSD (%) 
Sparfloxacin 30.0 29.8 ± 0.7; 0.1
60.0 60.1 ± 0.4; 0.7
90.0 91.4 ± 0.5; 1.0
Dexamethasone 10.0 10.0 ± 0.2; 0.4
20.0 20.1 ± 0.9; 0.5
30.0 30.2 ± 0.7; 0.7
* = Average of 5 analysis
TABLE II - Intra-Day and Inter-Day Precision of the Proposed HPLC Method
Drugs Actual Concentration (µg/mL) 
Intra-day Precision
Measured conc.; ± SD; RSD (%)
Inter-day precision
Measured conc.; ± SD; RSD (%)
Sparfloxacin 30.0 30.2 ± 0.4; 1.1 29.6 ± 0.7; 1.2
60.0 60.7 ± 0.8; 0.1 59.8 ± 0.8; 0.7
90.0 90.1 ± 0.4; 1.5 89.8 ± 1.2; 1.1
Dexamethasone 10.0 10.0 ± 0.1; 0.4 10.0 ± 0.2; 0.3
20.0 19.9 ± 0.2; 0.8 20.2 ± 0.5; 0.4
30.0 29.9 ± 0.5; 1.0 30.0 ± 0.5; 0.1
TABLE III - Robustness study of sparfloxacin
Chromatographic Conditions Assay % tR (min) Theoretical plates Tailing
Methanol:buffer (63:37) 100.1 3.221 4307 1.34
Methanol:buffer (60:40) 99.6 3.415 4358 1.34
Methanol:buffer (57:43) 101.5 3.515 4358 1.31
Flow rate (1.3 mL/min) 101.4 3.625 4398 1.32
Flow rate (1.5 mL/min) 100.8 3.415 4387 1.34
Flow rate (1.7 mL/min) 101.8 3.199 4325 1.34
Buffer (pH 2.8) 102.0 3.411 4358 1.32
Buffer (pH 3.0) 101.4 3.417 4322 1.34
Buffer (pH 3.2) 100.2 3.417 4378 1.34
100 and 150%) of the nominal analytical concentrations 
were prepared. Percentage recoveries along with standard 
deviation and relative standard deviations for each 
analyte (n=5) are given in (Table I). Recovery studies 
showed the method to be highly accurate and suitable 
for intended use.
Intra-day and inter-day precision was calculated to 
perform precision. Intra-day precision was measured by 
analyzing three different concentrations five times within 
the same day and inter-day precision were determined by 
evaluating the response of same solutions for three days. 
Relative standard deviation (RSD %) of the peak area was 
calculated to represent precision. The results of intra-day 
and inter-day precision are presented in (Table II).
Robustness of the method was performed by 
slightly varying the chromatographic conditions. The 
results showed negligible effect on the chromatographic 
parameters by slight variations in chromatographic 
conditions (Table III and Table IV).
Specificity of the developed method was evaluated 
by applying different stress conditions (acid, base, 
oxidation, thermal and photolytic) to sparfloxacin and 
dexamethasone in combination form. The chromatograms 
under different stress conditions are shown in (Figure 3). 
The results of stress studies are given in (Table V).
All the stress conditions applied were enough to 
degrade both the drugs. Comparison of the two drugs 
showed that sparfloxacin is more stable as compared to 
dexamethasone. Under acidic conditions dexamethasone 
was degraded up to 97.3% and sparfloxacin was degraded 
up to 93.7. Under basic stress dexamethasone was 
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degraded up to 96% and sparfloxacin was degraded up 
to 91.9%. Under oxidative stress dexamethasone was 
degraded up to 96% and sparfloxacin was degraded up to 
94.5%. Under thermal stress dexamethasone was degraded 
up to 96.4% and sparfloxacin was degraded up to 95.9%. 
Under photolytic stress conditions dexamethasone was 
degraded up to 97.0% and sparfloxacin was found to be 
stable under photolytic stress. From these stress studies 
it was concluded that dexamethasone and sparfloxacin 
are not stable in basic, acidic, thermal, oxidative and 
photolytic stress conditions. The degradation pattern of 
the drugs is very similar under basic and photolytic stress 
conditions.
In addition to the percentage degradation of each 
drug, a number of degradation products (impurities) 
were produced under acidic, basic, thermal, oxidative 
and photolytic stress conditions (Figure 3). Application 
of the proposed method was checked by analyzing 
the sparfloxacin and dexamethasone in commercially 
available pharmaceutical products. The results are 
provided in (Table VI) which showed high percentage 
recoveries and low RSD (%) values for both analytes. 
CONCLUSION
A simple, sensitive, isocratic and accurate reverse 
phase HPLC method is described for simultaneous 
determination of sparfloxacin and dexamethasone in 
pharmaceutical formulations. The proposed method was 
validated by testing its linearity, accuracy, precision, 
limits of detection and quantitation and specificity. The 
method was good enough to separate the peaks of active 
pharmaceutical ingredients (APIs) from the degradation 
products (produced during forced degradation studies). It 
is also clear from the chromatograms that both the active 
TABLE V - Stress Testing Results of sparfloxacin and dexamethasone
Nature
of stress
Storage 
Conditions 
Time
 (h) 
Amount of sparfloxacin Amount of dexamethasone Extent of
decompositionRemaining±RSD (%) Remaining±RSD (%)
5M HCl  (40 °C/ 75 % RH) 22 6.3 ± 2.5 (PPI=1.0000) 2.7 ± 2.3 (PPI=1.0000) Substantial
5M NaOH  (22 °C/ 49 % RH) 0.75 91.2 ± 1.4 (PPI=1.0000) 6.0 ± 2.1 (PPI=1.0000) Substantial
 (40 °C/ 75 % RH) 16 8.04 ± 1.4 (PPI=1.0000) 4.0 ± 3.1 (PPI=1.0000) Substantial
6% H2O2  (40 °C/ 75 % RH) 22 5.5 ± 1.0 (PPI=1.0000) 4.0 ± 1.1(PPI=1.0000) Substantial
Thermal  (40 °C/ 75 % RH) 22 4.1 ± 1.3 (PPI=1.0000) 3.6 ± 1.5 (PPI=1.0000) Substantial
Photolytic Sunlight 1.25 98.7 ± 1.2 (PPI=1.0000) 3.0 ± 2.4 (PPI=1.0000) Substantial
PPI= Peak Purity Index
TABLE IV - Robustness study of dexamethasone
Chromatographic Conditions Assay %  tR (min) Theoretical plates Tailing
Methanol:buffer (63:37) 100.4 7.214 2021 1.04
Methanol:buffer (60:40) 101.2 7.792 2074 1.04
Methanol:buffer (57:43) 102.0 8.311 2144 1.10
Flow rate (1.3 mL/min) 99.1 8.333 2254 1.10
Flow rate (1.5 mL/min) 99.5 7.792 2047 1.02
 Flow rate (1.7 mL/min) 100.5 7.169 2178 1.03
Buffer (pH 2.8) 101.6 7.697 2298 1.02
Buffer (pH 3.0) 100.7 7.792 2258 1.04
Buffer (pH 3.2) 100.2 7.798 2241 1.10
TABLE VI - Assay results of sparfloxacin and dexamethasone in 
commercial eye drops
Products
Eye drops Ingredient 
Label value
(mg/mL) 
% Recovery*
±RSD (%)
Spar-D Sparfloxacin 3 100.3 ± 0.3
Dexamethasone 1 99.0 ± 0.7
* = Average of 10 determination
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FIGURE - 3 A typical chromatogram of sparfloxacin (tR = 3.425) and dexamethasone (tR = 7.794) under acidic, basic, thermal, 
photolytic and oxidative stress conditions. Where (X) is sparfloxacin peak, (Y) dexamethasone peak, (1, 2, 3, 4, and 5) degradation/
impurities peaks, (A) chromatogram of oxidative stress, (B) chromatogram of thermal stress, (C) chromatogram of acidic stress, 
(D) chromatogram of basic stress and (E) chromatogram of photolytic stress. Chromatographic conditions: mobile phase methanol: 
0.02 M phosphate buffer (60:40, v/v), pH 3.0, Column BDS Hypersil C8 (250 X 4.6, 5 µm), flow rate 1.5 mL min-1, injection 
volume 20 µL, wavelength 270 nm.
ingredient peaks in all the stress conditions are free from 
any sort of degradation impurities. All these convince us 
to conclude that the method can be successfully used for 
any sort of stability and validation studies.
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